Huadong Medicine Co (SZSE:000963) Other Long-Term Liabilities: ¥425 Mil (As of Mar. 2026)


SZSE:000963 Huadong Medicine Co Ltd SZSE:000963
77 GF Score
Price ¥28.25
GF Value ¥39.42
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Huadong Medicine Co Other Long-Term Liabilities?

Huadong Medicine Co SZSE:000963 -2.32% 77 Other Long-Term Liabilities is ¥425 Mil as of Mar. 2026. GuruFocus rates SZSE:000963 with a GF Score™ of 77/100 and a GF Value™ of ¥39.42 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Huadong Medicine Co's other long-term liabilities for the quarter that ended in Mar. 2026 was ¥425 Mil.

Huadong Medicine Co's quarterly other long-term liabilities increased from Sep. 2025 (¥429 Mil) to Dec. 2025 (¥436 Mil) but then declined from Dec. 2025 (¥436 Mil) to Mar. 2026 (¥425 Mil).

Huadong Medicine Co's annual other long-term liabilities declined from Dec. 2023 (¥440 Mil) to Dec. 2024 (¥410 Mil) but then increased from Dec. 2024 (¥410 Mil) to Dec. 2025 (¥436 Mil).

Huadong Medicine Co Other Long-Term Liabilities Related Terms

Huadong Medicine Co Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Huadong Medicine Co's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Huadong Medicine Co Other Long-Term Liabilities Chart

Huadong Medicine Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 307.52 439.39 439.79 410.22 435.52

Huadong Medicine Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 405.87 409.72 429.24 435.52 424.52
SZSE:000963
77GF Score
Huadong Medicine Co Ltd SZSE:000963
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Huadong Medicine Co Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ¥425 Mil mean?
Huadong Medicine Co (SZSE:000963) has a Other Long-Term Liabilities of ¥425 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Huadong Medicine Co and its competitors.
Is Huadong Medicine Co's Other Long-Term Liabilities too high?
Huadong Medicine Co's current Other Long-Term Liabilities is ¥425 Mil. Overall, Huadong Medicine Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Huadong Medicine Co's Other Long-Term Liabilities compare to ZTS?
Huadong Medicine Co's Other Long-Term Liabilities of ¥425 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Huadong Medicine Co and its competitors. Huadong Medicine Co's current Other Long-Term Liabilities is ¥425 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Huadong Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Huadong Medicine Co (SZSE:000963) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥39.42, compared to a current price of ¥28.25 — trading 28.3% below its estimated fair value. The current Other Long-Term Liabilities is ¥425 Mil. Huadong Medicine Co's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Huadong Medicine Co (SZSE:000963), the current Other Long-Term Liabilities is ¥425 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Huadong Medicine Co (SZSE:000963) Overvalued in 2026?

Based on GuruFocus' analysis, Huadong Medicine Co stock appears to be undervalued. The current stock price of ¥28.25 is trading 28.3% below its estimated GF Value™ of ¥39.42. GuruFocus considers Huadong Medicine Co to be Modestly Undervalued.

Key valuation signals for SZSE:000963:

  • Other Long-Term Liabilities: ¥425 Mil
  • GF Value™: ¥39.42 vs. price of ¥28.25 (28.3% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the SZSE:000963 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Huadong Medicine Co Business Description

Address No. 866, Moganshan Road, Zhejiang Province, Hangzhou, CHN, 310011
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drug products. The company mainly operates its business through three segments. The Manufacturing Business segment is engaged in the research and development, production, and marketing of specialized medicines, medicines for chronic diseases, as well as special medicines. The Commercial Business segment is engaged in the sales of medicines, medical devices, ginseng, and antler pieces. The International Medical Beauty Business segment is engaged in the production and sales of regeneration products, hyaluronic acids, and botulinum toxin products.
77GF Score

Get the complete analysis for SZSE:000963

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥28.25
Price
¥39.42
GF Value